EPIX has been the topic of several other reports. HC Wainwright reissued a “buy” rating on shares of ESSA Pharma in a research report on Friday, May 17th. Zacks Investment Research raised shares of ESSA Pharma from a “sell” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Wednesday, May 22nd.
Shares of EPIX traded up $0.05 during mid-day trading on Tuesday, hitting $2.82. The company had a trading volume of 11,180 shares, compared to its average volume of 16,424. The business’s 50-day simple moving average is $2.21 and its 200-day simple moving average is $2.63. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 2.27. ESSA Pharma has a 1-year low of $1.41 and a 1-year high of $4.50. The stock has a market cap of $22.38 million, a PE ratio of -1.11 and a beta of 1.85.
ESSA Pharma Company Profile
ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Further Reading: What is a Stop Order?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.